A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.
|ClinicalTrials.gov Identifier: NCT00139672|
Recruitment Status : Completed
First Posted : August 31, 2005
Last Update Posted : June 17, 2008
|Condition or disease||Intervention/treatment||Phase|
|Irritable Bowel Syndrome||Drug: PD-217,014||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||330 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Investigate The Effect Of Pd-217,014 In Patients With Irritable Bowel Syndrome (IBS)|
|Study Start Date :||January 2004|
|Primary Completion Date :||February 2005|
|Study Completion Date :||February 2005|
- Assess the effect of PD-217,014 on the relief of abdominal pain/discomfort in patients with irritable bowel syndrome. Primary endpoint is a responder, defined by having adequate relief for > or = 50% of the active treatment period (4 weeks).
- Assess the effect of PD-217,014 on the patient's global assessment of IBS symptoms, stool frequency & consistency and on abdominal bloating (change from baseline to week 4).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00139672
|Study Director:||Pfizer CT.gov Call Center||Pfizer|